The Opportunity
The unprecedented convergence of multi-modal data, advanced disease modeling, and computational power is revolutionizing drug discovery. insitro is harnessing this moment to redefine how medicines are developed for complex diseases. Our AI/ML-enabled platforms integrate and scale data to rapidly discover novel biological insights, identify new targets and drugs, and redefine complex diseases. To enable this vision, we are seeking a Director (or Senior Director) of Translational Medicine and Diagnostics.
This role is an opportunity to directly improve patients' lives by leading translational medicine across our three therapeutic areas — neurology/neurodegeneration, metabolism/cardiovascular, and ophthalmology — and by making clinical trials more efficient and beneficial for patients and drug developers through AI/ML and innovative translational strategies.
Reporting directly to the Chief Medical Officer, you will lead the translational medicine function at insitro, supporting the development of multiple therapeutics — biologics, oligonucleotides, and small molecules — along with multimodal biomarkers and diagnostics. This position can be onsite (three days per week) or hybrid (~one week per month) in our South San Francisco office, with additional travel to relevant medical and translational science conferences and health authorities.
Responsibilities
Translational Strategy & Leadership
Build the Function: Build and lead insitro's translational medicine function, from IND/CTA through clinical proof-of-concept, across biologics, oligonucleotides, and small molecules
Lead Key Assets: Serve as translational lead for advanced pre-clinical and initial clinical-stage assets
Own End-to-End Strategy: Be accountable for translational medicine strategy, GCP adherence, and regulatory-authority interactions, including biospecimen CRO selection and oversight
Biomarker Science & Patient Stratification
Design Stratification Strategies: Design innovative approaches to patient stratification using laboratory and digital biomarkers
Generate Proof-of-Mechanism Evidence: Generate proof-of-mechanism evidence that drives objective, data-driven, and timely go/no-go decisions
Regulatory Strategy, Partnership & Influence
Interpret Regulatory Requirements: Interpret regulatory translational medicine requirements and quantify the return on investment of translational strategies
Partner Across Functions: Collaborate closely with preclinical, clinical, regulatory, and computational teams
Shape the Field: Influence emerging AI/ML policy in translational science through original publications, presentations, and stakeholder engagement
About You
Experience & Qualifications
Advanced Degree: Advanced degree in life sciences, technology, chemistry, or a related discipline, or equivalent practical experience
Proven Tenure: 10+ years of experience in translational science in biotech and/or pharma, including direct experience as a translational lead delivering therapeutics and diagnostic biomarkers from FIH through proof-of-concept to NDA/BLA submission
AI/ML Exposure: Experience applying AI/ML approaches to drug discovery and development
Technical Breadth: Deep understanding of diagnostic and device regulations, good clinical practice, clinical trial design and execution, clinical pharmacology, biostatistics, and the application of computation to drug development
Core Competencies
Cross-Functional Collaborator: Track record of communicating and collaborating effectively with diverse stakeholders across clinical, translational, computational, and life sciences functions
Motivating Leader: Strong interpersonal skills that inspire others to do their best work
Patient-Driven: Genuine passion for bringing better medicines to patients in need
Compensation & Benefits at insitro
Our target starting salary for successful US-based applicants for this role is $224,000 - $299,000. To determine starting pay, we consider multiple job-related factors including a candidate's skills, education and experience, market demand, business needs, and internal parity. We may also adjust this range in the future based on market data.
This role is eligible for participation in our Annual Performance Bonus Plan (based on company targets by role level and annual company performance) and our Equity Incentive Plan, subject to the terms of those plans and associated policies.
In addition, insitro also provides our employees:
401(k) plan with employer matching for contributions
Excellent medical, dental, and vision coverage as well as mental health and well-being support
Open, flexible vacation policy
Paid parental leave of at least 16 weeks to support parents who give birth, and 10 weeks for a new parent (inclusive of birth, adoption, fostering, etc)
Quarterly budget for books and online courses for self-development
New hire stipend for home office setup
Monthly cell phone & internet stipend
Access to free onsite baristas and daily lunch for employees who are either onsite or hybrid
Access to a free commuter bus network that provides transport to and from our South San Francisco HQ from locations all around the Bay Area
insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.
We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.
#LI-Hybrid
Please be aware of recruitment scams: we never request payments, all recruitment communications are from @insitro.com, and if in doubt, contact us at info@insitro.com.
About insitro
insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com.